UA-93693832-1skip to primary navigationskip to content

Shionogi areas of interest

Shionogi therapeutic and technology areas of interest

Shionogi is looking for novel hypotheses, targets and breakthrough technologies in the following areas:


  • Infectious Diseases
  • Antimicrobial resistance
  • Severe fungal infections
  • Chronic viral infections, e.g. HBV and HIV
  • Neurological disorders, e.g. ADHD and Alzheimer’s disease
  • Chronic pain
  • Translational biomarkers for neurological disorders and chronic pain    
  • Drug repositioning
  • Technology/platform innovations for drug discovery
300 Nao

Types of academic partnership with Shionogi

Shionogi has a variety of academic partnership models to meet the specific needs of individual projects. Shionogi can offer:

250 kai and nao

 

  • Research funding for agreed study proposals
  • Opportunities for sabbaticals at the Shionogi Pharmaceutical Research Center in Osaka, Japan
  • Collaborations between academic researchers and Shionogi scientists
  • Drug development expertise and knowhow from Shionogi scientists

 

 

                                                                                                                                                                                       

Open innovation, compound libraries and resources 

Shionogi can offer:

  • Shionogi compounds to find new therapeutic applications
  • Shionogi compound libraries for target discovery, validation, and hit to lead
  • Drug screening tools (in vitro and in vivo) available in Shionogi
  • Preclinical disease models to validate drug candidates (small molecules, antibodies, peptides etc.)
                                                                                                                                                                                      

Shionogi in Cambridge

Shionogi is one of the leading proponents of open innovation in the pharmaceutical sector. In true and equal partnerships, Shionogi has been collaborating with more than 50 universities/academic institutes worldwide, and now it is keen to establish research collaborations with scientists and clinicians in Cambridge.

As part of the Milner Therapeutics Consortium, these collaborations can be facilitated through match-making with individual researchers, or in meetings and workshops between groups of scientists working in relevant areas. For more information please contact Kathryn.Chapman@milner.cam.ac.uk

For more information on Shionogi click the logo here        175 logo shionogi T

 

 

 

       

 

 

 

       

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

        See Affiliated Companies